T1	Outcomes 0 45	Safety, pharmacokinetics and pharmocodynamics
T2	Outcomes 858 900	5-aminolevulinic acid and porphobilinogen.
T3	Outcomes 2398 2536	concentrations of recombinant human porphobilinogen deaminase and titres of antibodies against recombinant human porphobilinogen deaminase
T4	Outcomes 2561 2624	Plasma porphobilinogen and 5-aminolevulinic acid concentrations
T5	Outcomes 2708 2783	Urinary porphobilinogen, 5-aminolevulinic acid and porphyrin concentrations
T6	Outcomes 2796 2827	plasma porphyrin concentrations
T7	Outcomes 2989 3011	serious adverse events
T8	Outcomes 3139 3201	antibodies against recombinant human porphobilinogen deaminase
T9	Outcomes 3225 3249	allergic manifestations.
T10	Outcomes 3254 3349	mean elimination half-lives of the highest doses of recombinant human porphobilinogen deaminase
T11	Outcomes 3471 3517	area under the plasma concentration-time curve
T12	Outcomes 3621 3658	plasma porphobilinogen concentrations
T13	Outcomes 3825 3861	plasma porphobilinogen concentration
T14	Outcomes 3975 4018	plasma 5-aminolevulinic acid concentrations
T15	Outcomes 4060 4085	porphyrin concentrations.
T16	Outcomes 4090 4146	corresponding concentrations of metabolites in the urine
T17	Outcomes 4648 4668	therapeutic efficacy
